Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 211

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Open access
Jassem, Jacek, de Marinis, Filippo, Giaccone, Giuseppe, Vergnenegre, Alain, Barrios, Carlos H., Morise, Masahiro, Felip, Enriqueta, Oprean, Cristina, Kim, Young-Chul, Andric, Zoran, Mocci, Simonetta, Enquist, Ida, Komatsubara, Kimberly, McCleland, Mark, Kuriki, Hiroshi, Villalobos, Monette, Phan, See, Spigel, David R., Herbst, Roy S. · 2021 · Journal of Thoracic Oncology

Abstract

PURPOSE IMpower110 previously demonstrated significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR/ALK-negative (WT) metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (≥50% on tumor cells [TC] or ≥10% on tumor-infiltrating immune cells [IC], per SP142 immunohistochemistry assay). We present primary OS analyses in lower PD-L1 expression groups and an updated, exploratory analysis in the high PD-L1 expression group. PATIENTS AND METHODS This open-label, phase 3 trial randomized patients with PD-L1 expression on ≥1% of TC or IC to receive atezolizumab or platinum-based chemotherapy. The primary endpoint was OS, hierarchically tested in PD-L1 expression WT subgroups: first the high PD-L1 expression subgroup, then the high-or-intermediate PD-L1 expression subgroup (≥5% on TC or IC), and then the any PD-L1 expression subgroup (≥1% on TC or IC). RESULTS The any PD-L1 expression WT population included 554 patients (excluded 18 EGFR/ALK-positive patients). With 17 months' additional follow-up, OS improvement in the atezolizumab versus chemotherapy arm was not statistically significant in high-or-intermediate PD-L1 expression WT patients (n=328; HR, 0.87 [95% CI, 0.66-1.14]; P=0.3091; median, 19.9 vs 16.1 months), precluding formal OS testing in any PD-L1 expression WT patients. Exploratory analysis in high PD-L1 expression WT patients (n=205) showed maintained OS benefit in the atezolizumab arm (HR, 0.76 [95% CI, 0.54-1.09]; median, 20.2 vs 14.7 months). Updated safety data continued to favor atezolizumab. CONCLUSION Statistical significance for OS was not demonstrated in the high-or-intermediate expression WT group and, as a result, OS in the any PD-L1 expression WT group was not formally tested. No new safety signals were seen. This updated analysis of IMpower110 supports using atezolizumab in treatment-naive, metastatic WT NSCLC with high PD-L1 expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2021.06.019

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 211

Metadata

Authors
Jassem, J., de Marinis, F., Giaccone, G., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Oprean, C., Kim, Y.-C., Andric, Z., Mocci, S., Enquist, I., Komatsubara, K., McCleland, M., Kuriki, H., Villalobos, M., Phan, S., Spigel, D. R., & Herbst, R. S.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2021-11
Volume
16
Issue
11
Pages
1872-1882
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3182948012
Cited by
211
References
9
FWCI
10.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC. https://app.cochat.ai/papers/10.1016/j.jtho.2021.06.019
The paper
Jassem, J., de Marinis, F., Giaccone, G., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Oprean, C., Kim, Y.-C., Andric, Z., Mocci, S., Enquist, I., Komatsubara, K., McCleland, M., Kuriki, H., Villalobos, M., Phan, S., Spigel, D. R., & Herbst, R. S. (2021). Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2021.06.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.